Qure.ai, named a TIME100 Most Influential Company and recognized globally for its innovations in digital health, has announced a new collaboration with Microsoft. Through this partnership, Qure.ai will make its complete AI-driven lung cancer detection and management portfolio available on the Precision Imaging Network, enabling faster deployment for hospitals and health systems across the United States. The integration will support smoother digital transformation, stronger technology interoperability, and better clinical outcomes.
Qure.ai’s lung cancer solutions are built on advanced Large Language Models (LLMs) and Agentic AI. These tools enhance collaboration across care teams—from radiology and pulmonology to interventional and thoracic specialties—helping accelerate the path from early detection to diagnosis and treatment. Lung cancer remains the deadliest cancer in the U.S., responsible for more fatalities than breast, colon, and prostate cancers combined, making early and accurate identification critical.
Jim Mercadante, Chief Commercial Officer at Qure.ai, said “Our partnership with Microsoft brings greater flexibility and ease of adoption for U.S. health systems. Together, we aim to strengthen early detection, streamline triage, and improve patient tracking—supporting better survival rates while reducing costs. This collaboration expands our global ecosystem of partners across academia, government, pharma, life sciences, and technology. Through our long-term work with AstraZeneca and the EDISON Alliance, we recently marked a milestone of five million AI-analyzed chest scans across 20 countries, reinforcing how AI can help identify lung cancer risk earlier.”
Peter Durlach, Corporate VP and Chief Strategy Officer, Microsoft Health and Life Sciences, added
“Integrating Qure.ai into the Precision Imaging Network will help healthcare systems enhance efficiency—from quicker detection to more coordinated multidisciplinary care. This collaboration underscores Microsoft’s commitment to providing secure, scalable cloud AI solutions that support earlier interventions, improved outcomes, and long-term transformation.”
Qure.ai’s technology is now used in over 4,800 sites across more than 105 countries. The company earned a place on the TIME100 Most Influential Companies 2025 list for its role in reshaping diagnosis and access to care for major global diseases. Qure.ai currently holds 19 FDA clearances covering lung cancer and neurocritical condition detection and management.
Its FDA-cleared lung cancer products can be used individually or as a fully integrated suite, offering a unified workflow. Together, they cover the complete care pathway—from identifying incidental lung nodules on X-rays (qXR-LN), to measurement and quantification on CT scans (qCT-LN Quant), to coordinated patient follow-up (qTrack). Additionally, Qure.ai’sneurocritical AI solution (qER) supports emergency teams by rapidly flagging urgent findings.
Qure.ai is a global health technology company creating AI-powered tools that support early diagnosis and coordinated care. Its solutions help clinicians manage Tuberculosis, Lung Cancer, and Neurocritical conditions efficiently, benefiting both healthcare delivery and ongoing innovation across the pharmaceutical and medical device sectors. The company has a presence in more than 100 countries and regional offices in New York, London, Dubai, and Mumbai. Qure.ai is recognized as a TIME100 Most Influential Company for 2025.
